VC-backed Arcadia Biosciences goes public

By Iris Dorbian — 9 months ago

Davis, California-based Arcadia Biosciences, an agricultural products developer, has raised $65.6 million for its IPO after pricing its 8.2 million shares at $8 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “RKDA.” Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC are the lead underwriters. Arcadia’s backers include Mandala Capital Limited, CMEA Capital, BASF Venture Capital and Saints Capital.

Continue

Presidio Partners restructures CMEA funds

By Luisa Beltran — 10 months ago

Presidio Partners, the former CMEA Capital, said Tuesday that it restructured CMEA legacy funds IV, V and VI, with additional follow-on capital. The firm renamed the pool Presidio Partners 2014, a $142 million fund that manages 17 companies. CMEA VII fund has also been renamed Presidio Partners 2007, a $400 million fund with 19 companies. Presidio also said it promoted Peter Gajdos to the role of Managing Director and appointed Lee Pantuso to CFO.

Continue

VC-backed Arcadia Biosciences appoints O’Neil as CFO

By Iris Dorbian — 11 months ago

Davis, California-based Arcadia Biosciences, an agricultural products developer, has named Thomas P. O’Neil as chief financial officer. Previously, O’Neil worked at Sorbent Therapeutics Inc. Arcadia’s backers include Mandala Capital Limited, CMEA Capital, BASF Venture Capital and Saints Capital.

Continue

VC-backed Arcadia Biosciences files for IPO

By Iris Dorbian — 12 months ago

Davis, California-based Arcadia Biosciences, an agricultural products developer, has filed for an IPO. The number of shares that will be sold as well as the stock’s price range have yet to be set. Arcadia plans on trading its IPO on the NASDAQ under the ticker symbol “RKDA.” Credit Suisse Securities (USA) LLC and J.P. Morgan Securities LLC will be serving as the lead underwriters. Arcadia’s backers include Mandala Capital Limited, CMEA Capital, BASF Venture Capital and Saints Capital.

Continue

CMEA Capital expands team with two new additions

By Iris Dorbian — 2 years ago

San Francisco-based venture firm CMEA Capital has added Uday Sandhu and Drew Wilson to its investment and finance teams, respectively. Previously, Sandhu worked at TriplePoint Capital where he was an associate while Wilson worked at GSV Asset Management.

Continue

VC-backed Ardelyx debuts IPO

By Iris Dorbian — 2 years ago

Ardelyx has launched its IPO after pricing its approximately 4.3 million shares at $14 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “ARDX.” Citigroup and Leerink Partners are the lead underwriters. Based in Fremont, Calif., Ardelyx is a biopharmaceutical firm focused on cardio-renal, GI and metabolic diseases. Its backers include New Enterprise Associates, CMEA Capital and Amgen Ventures.

Continue

VC-backed Sorbent Therapeutics expands board of directors

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Sorbent Therapeutics closes first tranche in $15 mln Series D

By Iris Dorbian — 2 years ago

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has closed a $6.5 million tranche in a $15 million Series D financing. The investors were CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

Continue

Arcadia Biosciences snags $33 mln

By Iris Dorbian — 2 years ago

Arcadia Biosciences, a Davis, Calif-based agricultural biotech firm focused on the environment and human health, said Thursday that it has received $33 million in Series D financing. Mandala Capital Limited led the round with participation from CMEA Capital, BASF Venture Capital and Saints Capital. Piper Jaffray & Co. advised Arcadia on the transaction.

Continue

Sumeet Jain Joins Intel Capital From CMEA

By Mark Boslet — 3 years ago

Sumeet Jain announced on his blog that he has joined Intel Capital as an investment director to focus on consumer Internet, mobile Web and software investments. He was previously a partner at CMEA Capital, joining the firm in 2008 and sitting on boards at Apriso, Blekko, Intermolecular, Luminate, WorkingPoint and Zarly.

Continue

Takeda Pharmaceutical Buys VC-Backed Intellikine

4 years ago

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Continue

Intellikine Adds $4M in Milestone Payments

4 years ago

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Continue

Colorado PERA’s 10 Biggest Venture Capital Bets: Slideshow

By Mark Boslet — 4 years ago

The Colorado Public Employees’ Retirement Association has been an uneven investor in venture capital. Commitments have risen and fallen over the years without obvious pattern. In 2006, earmarked capital was $105 million, according to a peHUB analysis of its portfolio. A year earlier, it was $67 million. The year before it was $93 million, and […]

Continue

Blekko Inks $30M

4 years ago

Search engine company Blekko has raised $30 million in new funding, half of it coming from publicly traded Yandex. Australian investor MLC Private Equity, and existing investors U.S. Venture Partners, CMEA Capital and PivotNorth Capital also contributed to the round. Yandex acquired a minority stake in Blekko, the company said. Blekko was formed in 2007, and launched its search engine last year.

Continue

Update: Solyndra Looks Like Big Write-off For Redpoint, RockPort, CMEA, US Venture Partners

By Mark Boslet — 4 years ago

Solar experts have long anticipated a shakeout in the thin film solar industry. Thin film cells, a component of solar panels, offer the potential of low costs. But higher energy conversion efficiencies give competing crystalline silicon cells a market advantage, especially as Chinese firms pump out great volumes supported by inexpensive loans from state banks, lowering […]

Continue

Ardelyx Raises $30M Series B

4 years ago

Ardelyx Inc. has raised $30 million in fresh capital from New Enterprise Associates, CMEA Capital and new investor Amgen Ventures. The Series B round will help advance Ardelyx’s pharmaceutical pipeline that includes product candidates to help treat irritable bowel syndrome, chronic kidney disease and type 2 diabetes. The company has raised a total of $56 million since it was formed in 2007. Ardelyx is based in Fremont, Calif.

Continue

Pixazza Changes Name to Luminate

By Luisa Beltran — 5 years ago

Pixazza said Monday that it’s changing its name to Luminate. Mountain View, Calif.-based Luminate provides a platform for image applications. The company has received funding from August Capital, CMEA Capital, Google Ventures and Shasta Ventures.

Continue